Data gathered: July 2
AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated July 2, 2025. Powered by Chat GPT.
X4 Pharmaceuticals is a biotechnology company focused on developing novel therapies for rare diseases. The company aims to advance treatments for patients with significant unmet medical needs by leveraging its deep understanding of disease biology and innovative therapeutic approaches. X4 Pharmaceuticals is particularly known for its efforts in treating rare and orphan diseases through clinical research and development.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | July 2 Price is up by 8.6% in the last 24h. |
|
X4 Pharmaceuticals | June 30 Price is up by 7.4% in the last 24h. |
|
X4 Pharmaceuticals | June 27 Price is down by -8.5% in the last 24h. |
|
X4 Pharmaceuticals | June 25 Price is down by -8.7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 65 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,349 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,066 | Sign up | Sign up | Sign up |
| Twitter Mentions | 72 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 117 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $1.98 |
| Target Price | Sign up |
| Volume | 701,260 |
| Market Cap | $14M |
| Year Range | $1.83 - $24.24 |
| Dividend Yield | 0% |
| PE Ratio | 0.87 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Sees Large Growth in Short InterestJune 18 - ETF Daily News |
 |
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 15 - Yahoo |
|
Brokers Offer Predictions for XFOR FY2026 EarningsJune 11 - ETF Daily News |
|
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 9 - Yahoo |
|
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2 - Yahoo |
|
X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4% – Here’s What HappenedMay 26 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 29M | 4.7M | 24M | 280,000 | 3M | 0.040 |
| Q4 '24 | 1.4M | 300,000 | 1.1M | -40M | -37M | -0.200 |
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | -0.180 |
| Q2 '24 | 560,000 | 270,000 | 300,000 | 91M | -34M | -0.070 |
| Q1 '24 | 0 | 62,000 | -62,000 | -52M | -50M | -0.260 |
Insider Transactions View All
| Baldry Mark filed to buy 25,337 shares at $2.5. May 20 '25 |
| Arbet-Engels Christophe filed to sell 14,207 shares at $0.5. January 27 '25 |
| DiBiase Mary filed to sell 490,980 shares at $0.5. January 27 '25 |
| Baldry Mark filed to sell 94,123 shares at $0.5. January 27 '25 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of X4 Pharmaceuticals?
The Market Cap of X4 Pharmaceuticals is $14M.
What is X4 Pharmaceuticals' PE Ratio?
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 0.87.
What is the current stock price of X4 Pharmaceuticals?
Currently, the price of one share of X4 Pharmaceuticals stock is $1.98.
How can I analyze the XFOR stock price chart for investment decisions?
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
Does XFOR offer dividends to its shareholders?
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of X4 Pharmaceuticals?
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.